

[illegible]

|                    |                 |
|--------------------|-----------------|
| EXAMINER           | DATE CONSIDERED |
| <i>[Signature]</i> | <i>3/15/05</i>  |

|  |  |   |                               |                                 |
|--|--|---|-------------------------------|---------------------------------|
| PTO-1449 REPRODUCED  |  | ATTORNEY DOCKET NO.<br>3298.1001-000        | APPLICATION NO.<br>10/072,611 |                                 |
| <b>INFORMATION DISCLOSURE CITATION<br/>IN AN APPLICATION</b><br><br>March 22, 2004<br>(Indicate several sheets if necessary) |  | FIRST NAMED INVENTOR<br>Brian Leyland-Jones |                               | FILING DATE<br>February 8, 2002 |
|  |  | EXAMINER<br>C.J. Cheu                       | CONFIRMATION NO.<br>1456      | GROUP<br>1641                   |

| U.S. PATENT DOCUMENTS         |             |  |  |  |
|-------------------------------|-------------|--|--|--|
| EXAM-<br>INER<br>INI-<br>TIAL | REF.<br>NO. | DOCUMENT NUMBER<br>Number-Kind Code (if known) | ISSUE DATE /<br>PUBLICATION DATE<br>MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT<br>OF CITED DOCUMENT |
| <i>h</i>                      | AA          | 5,830,672                                      | 11-03-1998                                     | Wainer <i>et al.</i>                               |

| FOREIGN PATENT DOCUMENTS |    |  |                    |  |                       |
|--------------------------|----|--|--------------------|--|-----------------------|
|                          |    | DOCUMENT NUMBER<br>Country Code-Number-Kind Code<br>(if known) | DATE<br>MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT<br>OF CITED DOCUMENT | TRANSLATION<br>YES NO |
| <i>h</i>                 | AL | WO 00/55624 A2   | 09-21-2000         | Brian Leyland-Jones                                |                       |
| <i>h</i>                 | AM | EP 0921396 A2  | 06-09-1999         | Pfizer Products Inc.                               |                       |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |   |
|--|---|
| <i>h</i>   | AR<br>Tang, B.K., <i>et al.</i> , "Caffeine as a Metabolic Probe: Validation of its Use for Acetylator Phenotyping," <i>Clinical Pharmacology &amp; Therapeutics</i> , 49(6): 648-657 (1991).   |
| <i>h</i>   | AS<br>Kroemer, H.K. and Eichelbaum, M., "'It's the Genes, Stupid'. Molecular Bases and Clinical Consequences of Genetic Cytochrome P450 2D6 Polymorphism," <i>Life Sciences</i> , 56(26): 2285-2298 (1995).                                   |
| <i>h</i>   | AT<br>Wong, P., <i>et al.</i> , "A Competitive Enzyme Linked Immunosorbent Assay for the Determination of <i>N</i> -acetyltransferase (NAT2) Phenotypes," <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 13(9): 1079-1086 (1995). |
| <i>h</i>   | AU<br>Wong, P., <i>et al.</i> , "Syntheses of Caffeine Metabolites Derivatives for Measuring CYP1A2 Activity by ELISA," Proceedings of the 90th Annual Meeting of the American Association for Cancer Research, 40:53 (1999).                 |
| <i>h</i>   | AV<br>Wolf, C.R. and Smith, G., "Chapter 18. Cytochrome P450 CYP2D6," <i>Metabolic Polymorphisms and Susceptibility to Cancer</i> , 148:209-229 (1999).   |

|                              |                              |
|------------------------------|------------------------------|
| EXAMINER<br><i>C.H. Cheu</i> | DATE CONSIDERED<br>3/15/2015 |
|------------------------------|------------------------------|